Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D. Cohen; Luciano J. Costa; Madhav V. Dhodapkar; Francesca Gay; Nicole Gormley; Damian J. Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C. Pasquini; Noemi Puig; G. David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A. Shah; Qian Shi; Andrew Spencer; Vera J. Suman; Saad Z. Usmani; Philip L. McCarthy

doi:10.1016/j.bbmt.2020.06.011

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein, Alan Howard, David Avigan, Manisha Bhutani, Adam D. Cohen, Luciano J. Costa, Madhav V. Dhodapkar, Francesca Gay, Nicole Gormley, Damian J. Green, Jens Hillengass, Neha Korde, Zihai Li, Sham Mailankody, Paola Neri, Samir Parekh, Marcelo C. Pasquini, Noemi Puig, G. David Roodman, Mehmet Kemal SamurNina Shah, Urvi A. Shah, Qian Shi, Andrew Spencer, Vera J. Suman, Saad Z. Usmani, Philip L. McCarthy

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

Original language	English
Pages (from-to)	e247-e255
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2020.06.011
State	Published - Oct 2020

Keywords

CAR T cell
Endpoint
Immune profiling
Minimal residual disease
Multiple myeloma

Access to Document

10.1016/j.bbmt.2020.06.011

Cite this

Holstein, S. A., Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N., Green, D. J., Hillengass, J., Korde, N., Li, Z., Mailankody, S., Neri, P., Parekh, S., Pasquini, M. C., Puig, N., Roodman, G. D., ... McCarthy, P. L. (2020). Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 26(10), e247-e255. https://doi.org/10.1016/j.bbmt.2020.06.011

@article{215dce03a29d4325b8700cc23fa11cfb,

title = "Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",

abstract = "The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.",

keywords = "CAR T cell, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",

author = "Holstein, {Sarah A.} and Alan Howard and David Avigan and Manisha Bhutani and Cohen, {Adam D.} and Costa, {Luciano J.} and Dhodapkar, {Madhav V.} and Francesca Gay and Nicole Gormley and Green, {Damian J.} and Jens Hillengass and Neha Korde and Zihai Li and Sham Mailankody and Paola Neri and Samir Parekh and Pasquini, {Marcelo C.} and Noemi Puig and Roodman, {G. David} and Samur, {Mehmet Kemal} and Nina Shah and Shah, {Urvi A.} and Qian Shi and Andrew Spencer and Suman, {Vera J.} and Usmani, {Saad Z.} and McCarthy, {Philip L.}",

note = "Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grant U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the views or policies of the FDA. Conflict of interest statement: S.A.H. has served on advisory boards for Adaptive Biotechnologies, Celgene, Genentech, Oncopeptides, and Takeda and has served as a consultant for GlaxoSmithKline, Celgene, and Sorrento. D.A. has served on advisory boards for Celgene, Juno, Partners Tx, Karyopharm, Bristol-Myers Squibb, Aviv MedTech, and Takeda; has served as a consultant for Janssen, Parexel, Takeda, and Kite Pharma; has received research support from Celgene, Kite Pharma, and Pharmacyclics. M.B. has served on speakers{\textquoteright} bureaus for Amgen, Bristol-Myers Squibb, and Takeda; has served as a consultant for Sanofi Genzyme; and has received research funding from Janssen, MedImmune, Takeda, and Prothena. A.D.C. has served on advisory boards or as a consultant for Celgene/Bristol-Myers Squibb, Takeda, Janssen, GlaxoSmithKline, Oncopeptides, Seattle Genetics, and Kite Pharma; has received research support from Novartis; and has intellectual property licensed by his institution on his behalf from Novartis. L.J.C. has received research funding from Janssen and Amgen and has received consulting honorarium from Adaptive Biotechnologies, Celgene, Sanofi, and Karyopharm. M.V.D. has served on advisory boards for Amgen, Janssen, Lava Therapeutics, and Roche. F.G. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda and has served on advisory boards for Janssen, Celgene, Bristol-Myers Squibb, Amgen, Takeda, Adaptive Biotechnologies, Roche, Abbvie, and Oncopeptides. D.J.G. has served on advisory boards or as a consultant for Juno Therapeutics, Celgene, Seattle Genetics, Cellectar, and GlaxoSmithKline; has received research funding from Juno Therapeutics/Bristol-Myers Squibb, Merck, Sanofi, and Cellectar; and has intellectual property pending patents through his institution that relate to the combination of a small molecule with BMCA CAR T cell therapy. J.H. has served on advisory boards for Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Oncotracker. Z.L. serves on scientific advisory boards for Alphamab and Henlius Biotech; and serves as a consultant for Heat Biologics. S.M. has received clinical trial support from Allogene, Juno/ Bristol-Myers Squibb, Janssen, and Takeda and has received honoraria for CME activity from Physician Education Resource and Plexus Communications. P.N. has served on speakers{\textquoteright} bureaus and/or received honoraria from Amgen, Celgene, Janssen, and Takeda and has received consulting fees from Celgene, Janssen, and Takeda. S.P. is a consultant for Foundation Medicine and has received research funding from Celgene and Karyopharm. M.C.P. has served as a consultant for Bristol-Myers Squibb and Amgen and has received research support from Kite, Novartis, and Bristol-Myers Squibb. N.P. has received honoraria from Amgen, Celgene, Janssen, Takeda, and Binding Site; has served as a member of a scientific advisory board for Amgen, Celgene, Janssen, and Takeda; has served on speakers{\textquoteright} bureaus for Celgene; and has received research funding from Celgene, Janssen, Amgen, and Takeda. G.D.R. has received consulting honoraria from Amgen. N.S. has received research funding from Celgene, Janssen, Bluebird Bio, Sutro biopharma, and Teneobio; has served as an advisor for Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision Biosciences, GlaxoSmithKline, Nektar, Amgen, Indapta Therapeutics, Sanofi, Bristol-Myers Squibb, and CareDx; and has stock ownership in Indapta Therapeutics. U.A.S. has received honoraria from Physician's Education Resource and research funding from Celgene. S.Z.U. has received research funding from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda; and has received speaking fees from Amgen, Celgene, Janssen, and Takeda. P.L.M. has served as a consultant for Bird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page e254. Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grant U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the views or policies of the FDA. Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = oct,

doi = "10.1016/j.bbmt.2020.06.011",

language = "English",

volume = "26",

pages = "e247--e255",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier BV",

number = "10",

}

Holstein, SA, Howard, A, Avigan, D, Bhutani, M, Cohen, AD, Costa, LJ, Dhodapkar, MV, Gay, F, Gormley, N, Green, DJ, Hillengass, J, Korde, N, Li, Z, Mailankody, S, Neri, P, Parekh, S, Pasquini, MC, Puig, N, Roodman, GD, Samur, MK, Shah, N, Shah, UA, Shi, Q, Spencer, A, Suman, VJ, Usmani, SZ & McCarthy, PL 2020, 'Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling', Biology of Blood and Marrow Transplantation, vol. 26, no. 10, pp. e247-e255. https://doi.org/10.1016/j.bbmt.2020.06.011

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. / Holstein, Sarah A.; Howard, Alan; Avigan, David et al.
In: Biology of Blood and Marrow Transplantation, Vol. 26, No. 10, 10.2020, p. e247-e255.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

AU - Holstein, Sarah A.

AU - Howard, Alan

AU - Avigan, David

AU - Bhutani, Manisha

AU - Cohen, Adam D.

AU - Costa, Luciano J.

AU - Dhodapkar, Madhav V.

AU - Gay, Francesca

AU - Gormley, Nicole

AU - Green, Damian J.

AU - Hillengass, Jens

AU - Korde, Neha

AU - Li, Zihai

AU - Mailankody, Sham

AU - Neri, Paola

AU - Parekh, Samir

AU - Pasquini, Marcelo C.

AU - Puig, Noemi

AU - Roodman, G. David

AU - Samur, Mehmet Kemal

AU - Shah, Nina

AU - Shah, Urvi A.

AU - Shi, Qian

AU - Spencer, Andrew

AU - Suman, Vera J.

AU - Usmani, Saad Z.

AU - McCarthy, Philip L.

N1 - Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grant U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the views or policies of the FDA. Conflict of interest statement: S.A.H. has served on advisory boards for Adaptive Biotechnologies, Celgene, Genentech, Oncopeptides, and Takeda and has served as a consultant for GlaxoSmithKline, Celgene, and Sorrento. D.A. has served on advisory boards for Celgene, Juno, Partners Tx, Karyopharm, Bristol-Myers Squibb, Aviv MedTech, and Takeda; has served as a consultant for Janssen, Parexel, Takeda, and Kite Pharma; has received research support from Celgene, Kite Pharma, and Pharmacyclics. M.B. has served on speakers’ bureaus for Amgen, Bristol-Myers Squibb, and Takeda; has served as a consultant for Sanofi Genzyme; and has received research funding from Janssen, MedImmune, Takeda, and Prothena. A.D.C. has served on advisory boards or as a consultant for Celgene/Bristol-Myers Squibb, Takeda, Janssen, GlaxoSmithKline, Oncopeptides, Seattle Genetics, and Kite Pharma; has received research support from Novartis; and has intellectual property licensed by his institution on his behalf from Novartis. L.J.C. has received research funding from Janssen and Amgen and has received consulting honorarium from Adaptive Biotechnologies, Celgene, Sanofi, and Karyopharm. M.V.D. has served on advisory boards for Amgen, Janssen, Lava Therapeutics, and Roche. F.G. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda and has served on advisory boards for Janssen, Celgene, Bristol-Myers Squibb, Amgen, Takeda, Adaptive Biotechnologies, Roche, Abbvie, and Oncopeptides. D.J.G. has served on advisory boards or as a consultant for Juno Therapeutics, Celgene, Seattle Genetics, Cellectar, and GlaxoSmithKline; has received research funding from Juno Therapeutics/Bristol-Myers Squibb, Merck, Sanofi, and Cellectar; and has intellectual property pending patents through his institution that relate to the combination of a small molecule with BMCA CAR T cell therapy. J.H. has served on advisory boards for Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Oncotracker. Z.L. serves on scientific advisory boards for Alphamab and Henlius Biotech; and serves as a consultant for Heat Biologics. S.M. has received clinical trial support from Allogene, Juno/ Bristol-Myers Squibb, Janssen, and Takeda and has received honoraria for CME activity from Physician Education Resource and Plexus Communications. P.N. has served on speakers’ bureaus and/or received honoraria from Amgen, Celgene, Janssen, and Takeda and has received consulting fees from Celgene, Janssen, and Takeda. S.P. is a consultant for Foundation Medicine and has received research funding from Celgene and Karyopharm. M.C.P. has served as a consultant for Bristol-Myers Squibb and Amgen and has received research support from Kite, Novartis, and Bristol-Myers Squibb. N.P. has received honoraria from Amgen, Celgene, Janssen, Takeda, and Binding Site; has served as a member of a scientific advisory board for Amgen, Celgene, Janssen, and Takeda; has served on speakers’ bureaus for Celgene; and has received research funding from Celgene, Janssen, Amgen, and Takeda. G.D.R. has received consulting honoraria from Amgen. N.S. has received research funding from Celgene, Janssen, Bluebird Bio, Sutro biopharma, and Teneobio; has served as an advisor for Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision Biosciences, GlaxoSmithKline, Nektar, Amgen, Indapta Therapeutics, Sanofi, Bristol-Myers Squibb, and CareDx; and has stock ownership in Indapta Therapeutics. U.A.S. has received honoraria from Physician's Education Resource and research funding from Celgene. S.Z.U. has received research funding from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda; and has received speaking fees from Amgen, Celgene, Janssen, and Takeda. P.L.M. has served as a consultant for Bird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page e254. Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grant U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the views or policies of the FDA. Publisher Copyright: © 2020 American Society for Transplantation and Cellular Therapy

PY - 2020/10

Y1 - 2020/10

N2 - The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

AB - The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.

KW - CAR T cell

KW - Endpoint

KW - Immune profiling

KW - Minimal residual disease

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85087955631&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.06.011

DO - 10.1016/j.bbmt.2020.06.011

M3 - Review article

C2 - 32589921

AN - SCOPUS:85087955631

SN - 1083-8791

VL - 26

SP - e247-e255

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Abstract

Keywords

Access to Document

Fingerprint

Cite this